AegirBio AB (publ) Stocks

SEK 0Last Updated 23.03.2026

Issuer Rating

Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

SEK 1.65M

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

AegirBio AB (publ), a diagnostic company, develops and commercializes tests to follow the dosage of biological drugs. The company focuses on therapeutic drug monitoring of biologic therapies in the multiple sclerosis, cancer, and autoimmune diseases. It offers moNATor, a first dose-monitoring laboratory test to test multiple sclerosis for healthcare professionals and patients; and Viraspec, a COVID-19 saliva test kit. The company was incorporated in 2019 and is based in Lund, Sweden.

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks